An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo
- 7 April 2009
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (14), 5825-5830
- https://doi.org/10.1073/pnas.0811706106
Abstract
Aldosterone produces a multitude of effects in vivo, including promotion of postmyocardial infarction adverse cardiac remodeling and heart failure progression. It is produced and secreted by the adrenocortical zona glomerulosa (AZG) cells after angiotensin II (AngII) activation of AngII type 1 receptors (AT(1)Rs). Until now, the general consensus for AngII signaling to aldosterone production has been that it proceeds via activation of G(q/11)-proteins, to which the AT(1)R normally couples. Here, we describe a novel signaling pathway underlying this AT(1)R-dependent aldosterone production mediated by beta-arrestin-1 (betaarr1), a universal heptahelical receptor adapter/scaffolding protein. This pathway results in sustained ERK activation and subsequent up-regulation of steroidogenic acute regulatory protein, a steroid transport protein regulating aldosterone biosynthesis in AZG cells. Also, this betaarr1-mediated pathway appears capable of promoting aldosterone turnover independently of G protein activation, because treatment of AZG cells with SII, an AngII analog that induces betaarr, but not G protein coupling to the AT(1)R, recapitulates the effects of AngII on aldosterone production and secretion. In vivo, increased adrenal betaarr1 activity, by means of adrenal-targeted adenoviral-mediated gene delivery of a betaarr1 transgene, resulted in a marked elevation of circulating aldosterone levels in otherwise normal animals, suggesting that this adrenocortical betaarr1-mediated signaling pathway is operative, and promotes aldosterone production and secretion in vivo, as well. Thus, inhibition of adrenal betaarr1 activity on AT(1)Rs might be of therapeutic value in pathological conditions characterized and aggravated by hyperaldosteronism.Keywords
This publication has 38 references indexed in Scilit:
- Modulation of Adrenal Catecholamine Secretion by In Vivo Gene Transfer and Manipulation of G Protein–coupled Receptor Kinase-2 ActivityMolecular Therapy, 2008
- β-Arrestin-biased ligands at seven-transmembrane receptorsTrends in Pharmacological Sciences, 2007
- Transduction of Receptor Signals by ß-ArrestinsScience, 2005
- Adrenocortical cell linesMolecular and Cellular Endocrinology, 2004
- A β-Arrestin-dependent Scaffold Is Associated with Prolonged MAPK Activation in Pseudopodia during Protease-activated Receptor-2-induced ChemotaxisPublished by Elsevier BV ,2003
- Subcellular Localization of β-Arrestins Is Determined by Their Intact N Domain and the Nuclear Export Signal at the C TerminusPublished by Elsevier BV ,2003
- Mineralocorticoid and Angiotensin Receptor Antagonism During HyperaldosteronemiaHypertension, 2002
- Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological FunctionsEndocrine Reviews, 2001
- Modulation of the Arrestin-Clathrin Interaction in CellsPublished by Elsevier BV ,1997
- Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin- II-responsive aldosterone secretionEndocrinology, 1993